• FDA APPROVAL DATE: 4/22/2021
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known
  • PREGNANCY: Based on its mechanism of action, dostarlimab can cause fetal harm when administered in pregnancy. Contraception is advised.

Dostarlimab may cause immune-mediated adverse reactions.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric